Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL R GRUNWALD

Allopathic & Osteopathic Physicians Internal Medicine Hematology

NPI
1356495949
CMS profile
334168
Location
CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$92,567.51

85 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $77,493.40 76
Honoraria $13,860.00 5
Travel and Lodging $1,193.83 3
Food and Beverage $20.28 1

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Daiichi Sankyo Inc. $57,826.40 68
Astellas Pharma Global Development $6,200.00 2
PFIZER INC. $6,000.00 2
Celgene Corporation $4,844.00 2
Blueprint Medicines Corporation $3,960.00 1
Pharmacosmos Therapeutics Inc. $2,714.11 5
Servier Pharmaceuticals LLC $2,500.00 1
Stemline Therapeutics Inc. $2,400.00 1
AbbVie Inc. $2,100.00 1
E.R. Squibb & Sons, L.L.C. $2,076.00 1
Amgen Inc. $1,947.00 1

Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL R GRUNWALD

NPI 1356495949 · CMS profile ID 334168

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology

CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1356495949?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL R GRUNWALD, NPI 1356495949, CMS profile ID 334168. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1356495949?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). MICHAEL R GRUNWALD, NPI 1356495949, CMS profile ID 334168. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1356495949?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
MICHAEL R GRUNWALD, NPI 1356495949, CMS profile ID 334168, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1356495949?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

85 matching records · $92,567.51 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 85 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–85 of 85.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Daiichi Sankyo Inc. $967.5003/30/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836240305 CMS
Daiichi Sankyo Inc. $3,010.0003/25/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836240269 CMS
Daiichi Sankyo Inc. $107.5003/25/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836240273 CMS
Daiichi Sankyo Inc. $322.5003/25/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836240277 CMS
Daiichi Sankyo Inc. $322.5003/05/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836240237 CMS
Daiichi Sankyo Inc. $161.2503/05/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836240241 CMS
Daiichi Sankyo Inc. $161.2502/25/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836240173 CMS
Daiichi Sankyo Inc. $322.5002/25/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836240177 CMS
Daiichi Sankyo Inc. $387.0002/23/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836240161 CMS
Daiichi Sankyo Inc. $322.5002/23/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836240165 CMS
Daiichi Sankyo Inc. $161.2502/23/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836240169 CMS
Daiichi Sankyo Inc. $322.5002/16/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836240153 CMS
Daiichi Sankyo Inc. $258.0002/16/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836240157 CMS
Astellas Pharma Global Development $3,100.0002/12/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801077243 CMS
Daiichi Sankyo Inc. $1,935.0002/09/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836240209 CMS
Daiichi Sankyo Inc. $215.0002/09/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836240213 CMS
Daiichi Sankyo Inc. $322.5002/09/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836240217 CMS
Daiichi Sankyo Inc. $2,902.5002/05/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836240181 CMS
Daiichi Sankyo Inc. $483.7502/05/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836240185 CMS
Daiichi Sankyo Inc. $161.2502/05/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836240189 CMS
Daiichi Sankyo Inc. $2,257.5002/05/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836240193 CMS
Daiichi Sankyo Inc. $709.5002/05/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836240197 CMS
Daiichi Sankyo Inc. $645.0002/05/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836240201 CMS
Daiichi Sankyo Inc. $322.5002/05/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836240205 CMS
Daiichi Sankyo Inc. $1,290.0001/26/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836240057 CMS
Stemline Therapeutics Inc. $2,400.0001/21/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834863727 CMS
Daiichi Sankyo Inc. $258.0001/14/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836240053 CMS
PFIZER INC. $4,000.0001/14/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833388929 CMS
Daiichi Sankyo Inc. $387.0001/12/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836240049 CMS
Daiichi Sankyo Inc. $1,290.0001/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836240025 CMS
Daiichi Sankyo Inc. $516.0001/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836240029 CMS
Daiichi Sankyo Inc. $322.5001/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836240033 CMS
Daiichi Sankyo Inc. $1,935.0001/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836240037 CMS
Daiichi Sankyo Inc. $1,451.2501/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836240041 CMS
Daiichi Sankyo Inc. $754.6501/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836240045 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $28,091.64 61
PY2020 $51,865.37 48
PY2021 $92,567.51 85
PY2022 $41,180.37 31
PY2023 $20,814.31 32
PY2024 $45,228.53 55
PY2025 $63,867.04 74

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $477,353.20 39
PY2024 Principal investigator $112,160.00 12
PY2023 Principal investigator $157,681.01 18
PY2022 Principal investigator $104,388.73 12
PY2021 Principal investigator $44,622.95 28
PY2020 Principal investigator $99,150.96 28
PY2019 Principal investigator $166,942.73 69

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

39 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $1,089.60 12/31/2025 Non-covered Recipient Entity
Levine Cancer Institute
A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study to Evaluate the Efficacy and Safety of Bomedemstat MK-3543 versus Hydroxyurea in Cytoreductive Therapy Na ve Essential Thrombocythemia Participants No dispute reported 06/30/2026 1232928508
Principal investigator 1 Merck Sharp & Dohme LLC $229.60 12/31/2025 Non-covered Recipient Entity
Wake Forest Baptist Health-Internal Medicine, Section on Hematology & Oncology
A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study to Evaluate the Efficacy and Safety of Bomedemstat MK-3543 versus Hydroxyurea in Cytoreductive Therapy Na ve Essential Thrombocythemia Participants No dispute reported 06/30/2026 1232928560
Principal investigator 1 Janssen Research & Development, LLC $2,928.00 12/29/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIEN
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175338563
Principal investigator 1 Janssen Research & Development, LLC $6,798.00 12/29/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIEN
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175338583
Principal investigator 1 Janssen Research & Development, LLC $32,565.00 12/22/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIEN
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175338824
Principal investigator 1 Janssen Research & Development, LLC $6,186.00 12/12/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIEN
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175338980
Principal investigator 1 Incyte Corporation $8,725.00 12/11/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY
A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE) No dispute reported 06/30/2026 1240615954
Principal investigator 1 Incyte Corporation $4,002.00 12/11/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY
A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE) No dispute reported 06/30/2026 1240615957
Principal investigator 1 Incyte Corporation $39,894.00 12/11/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY
A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE) No dispute reported 06/30/2026 1240615961
Principal investigator 1 Incyte Corporation $595.00 12/11/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY
A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE) No dispute reported 06/30/2026 1240615966
Principal investigator 1 Janssen Research & Development, LLC $12,372.00 11/17/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIEN
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175339050
Principal investigator 1 Janssen Research & Development, LLC $17,721.00 11/10/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIEN
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175339090
Principal investigator 1 National Marrow Donor Program $845.00 11/07/2025 Covered Recipient Teaching Hospital
Atrium Health Cabarrus
Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events (MEASURE) No dispute reported 06/30/2026 1249326145
Principal investigator 1 Incyte Corporation $21,760.00 10/23/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY
A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE) No dispute reported 06/30/2026 1240615940
Principal investigator 1 Incyte Corporation $10,880.00 10/23/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY
A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE) No dispute reported 06/30/2026 1240615946
Principal investigator 1 Incyte Corporation $13,440.00 10/15/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY
A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE) No dispute reported 06/30/2026 1240615910
Principal investigator 1 Incyte Corporation $7,040.00 10/15/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY
A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE) No dispute reported 06/30/2026 1240615914
Principal investigator 1 Incyte Corporation $1,280.00 10/15/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY
A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE) No dispute reported 06/30/2026 1240615918
Principal investigator 1 Incyte Corporation $3,712.00 10/15/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY
A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE) No dispute reported 06/30/2026 1240615922
Principal investigator 1 Incyte Corporation $38,109.00 10/15/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY
A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE) No dispute reported 06/30/2026 1240615925
Principal investigator 1 Incyte Corporation $19,200.00 10/15/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY
A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE) No dispute reported 06/30/2026 1240615931
Principal investigator 1 Incyte Corporation $2,853.00 10/15/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY
A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE) No dispute reported 06/30/2026 1240615934
Principal investigator 1 Incyte Corporation $10,240.00 10/15/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY
A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE) No dispute reported 06/30/2026 1240615951
Principal investigator 1 Janssen Research & Development, LLC $12,809.00 10/09/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIEN
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175338916
Principal investigator 1 Janssen Research & Development, LLC $13,411.00 09/01/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIEN CES
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175339180
Principal investigator 1 National Marrow Donor Program $9,088.00 08/15/2025 Covered Recipient Teaching Hospital
Atrium Health Cabarrus
A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation No dispute reported 06/30/2026 1249326143
Principal investigator 1 Janssen Research & Development, LLC $5,928.00 08/07/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIEN CES
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175338768
Principal investigator 1 National Marrow Donor Program $935.00 08/01/2025 Covered Recipient Teaching Hospital
Atrium Health Cabarrus
Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events (MEASURE) No dispute reported 06/30/2026 1249326147
Principal investigator 1 Janssen Research & Development, LLC $29,880.00 07/28/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIEN CES
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175338760
Principal investigator 1 Janssen Research & Development, LLC $4,920.00 06/30/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIEN CES
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175339144
Principal investigator 1 Janssen Research & Development, LLC $26,245.00 06/09/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIEN CES
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175338774
Principal investigator 1 Janssen Research & Development, LLC $23,844.00 05/05/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIEN CES
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175338630
Principal investigator 1 Janssen Research & Development, LLC $15,434.00 03/31/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIEN CES
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175338719
Principal investigator 1 Incyte Corporation $24,146.00 03/27/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY
A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE) No dispute reported 06/30/2026 1240615906
Principal investigator 1 Janssen Research & Development, LLC $1,984.00 03/07/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIEN CES
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175339100
Principal investigator 1 National Marrow Donor Program $5,338.00 02/07/2025 Covered Recipient Teaching Hospital
Atrium Health Cabarrus
Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events (MEASURE) No dispute reported 06/30/2026 1249325917
Principal investigator 1 Janssen Research & Development, LLC $20,397.00 02/03/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIEN CES
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175338646
Principal investigator 1 National Marrow Donor Program $500.00 01/31/2025 Covered Recipient Teaching Hospital
Atrium Health Cabarrus
Facilitating Activation of Study Trials (FAST) No dispute reported 06/30/2026 1249325251
Principal investigator 1 Incyte Corporation $20,030.00 01/03/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY
A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE) No dispute reported 06/30/2026 1240615969